

[FDA Home](#)<sup>3</sup> [Drug Databases](#)<sup>4</sup> [Orange Book](#)<sup>5</sup>

## Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Search results from the "OB\_Rx" table for query on "022180."

Active Ingredient:	FERUMOXYTOL
Dosage Form;Route:	SOLUTION;INTRAVENOUS
Proprietary Name:	FERAHEME
Applicant:	AMAG PHARMS INC
Strength:	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)
Application Number:	N022180
Product Number:	001
Approval Date:	Jun 30, 2009
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

[Return to Electronic Orange Book Home Page](#)<sup>6</sup>

FDA/Center for Drug Evaluation and Research  
Office of Generic Drugs  
Division of Labeling and Program Support  
Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through January 2015

Patent and Generic Drug Product Data Last Updated March 06, 2015

### Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency Website](#)  
[Policies](#)

U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
Ph. 1-888-INFO-FDA (1-888-463-6332)  
[Email FDA](#)



[For Government For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#)  
[Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#)  
[Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



U.S. Department of Health & Human Services

---

**Links on this page:**

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/Drugs/InformationOnDrugs/default.htm)
6. [../default.cfm](http://www.fda.gov/Drugs/InformationOnDrugs/default.htm)

[FDA Home](#)<sup>3</sup> [Drug Databases](#)<sup>4</sup> [Orange Book](#)<sup>5</sup>

### Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 022180 Product 001 in the OB\_Rx list.

#### Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N022180	001	8599498	Jun 30, 2023	Y	Y		
N022180	001	7553479	Mar 8, 2020	Y	Y		
N022180	001	7871597	Mar 8, 2020	Y	Y		
N022180	001	8501158	Mar 8, 2020			U - 1422	
N022180	001	8591864	Mar 8, 2020		Y		
N022180	001	8828947	Mar 8, 2020	Y	Y		

#### Exclusivity Data

There is no unexpired exclusivity for this product.

#### Additional Information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.63(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)<sup>6</sup>

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - Monthly

Generic Drug Product Information & Patent Information - Daily

Orange Book Data Updated Through January 2015

Patent and Generic Drug Product Data Last Updated March 08, 2015

#### Links on this page:

1. <http://www.addthis.com/bookmark.php?v=508=true&v=152&username=fda@mail>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
Ph. 1-888-INFO-FDA (1-888-463-6332)  
[Email FDA](#)



For Government For Press

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry Health Professionals](#) [FDA Archive](#)



U.S. Department of Health & Human Services

#### Links on this page:

1. <http://www.addthis.com/bookmark.php?v=508=true&v=152&username=fda@mail>
2. <http://www.addthis.com/bookmark.php>

3/9/2015

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/Drugs/InformationOnDrugs/default.htm)
6. [../default.cfm](http://www.fda.gov/Drugs/InformationOnDrugs/default.htm)